Department of Urology, Division of Pediatric Urology, School of Medicine, Marmara University, Istanbul, Turkey.
Department of Urology, School of Medicine, Koç University, Istanbul, Turkey.
Neurourol Urodyn. 2024 Apr;43(4):1003-1018. doi: 10.1002/nau.25382. Epub 2024 Jan 18.
The aim of this systematic review is to assess urinary biomarkers studied in children with neurogenic and non-neurogenic lower urinary tract dysfunction (LUTD).
The systematic review was conducted in accordance with the PRISMA guidelines. The screening was performed on PUBMED without any publication date limitation. Only original articles were included. Parameters related to the following topics were obtained: study design, characteristics of participants, number of participants, age, control group, types of biomarkers, measurement technique in urine, subgroup analysis, urodynamic findings, and outcome. Dutch Cochrane Checklist (DCC) and level of evidence by EBRO platform were used for quality assessment. Meta-analysis was performed with the Comprehensive Meta-Analysis Version 4 program.
A total of 494 studies were screened and 16 studies were included. 11 (68.75%) were conducted in children with non-neurogenic LUTD and 5 (31.25%) neurogenic LUTD. Nerve growth factor (NGF) was evaluated in 12 studies, brain-derived neurotrophic factor (BDNF) in 5, Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) in 2, transforming growth factor beta-1 (TGF Beta-1) in 2, neutrophil gelatinase-associated lipocalin (NGAL) in 1, and Aquaporin-2 in 1. According to DCC, 10 (62.5%) articles were evaluated on 4 (37.5%) items and 4 articles on 5 items. The average score was 3.91+/-0.56. The level of evidence was found as B for 13 (81.25%) articles and C for 3 (18.75%). In meta-analysis, urinary NGF levels in children with non-neurogenic LUTS were significantly higher than in the healthy control group (Hedges's g = 1.867, standard error = 0.344, variance = 0.119, p = 0.0001).
Urinary biomarkers are promising for the future with their noninvasive features. However, prospective studies with larger sample sizes are needed to better understand the potential of urinary biomarkers to reflect urodynamic and clinical findings in children with LUTD.
本系统评价旨在评估在患有神经源性和非神经源性下尿路功能障碍(LUTD)的儿童中研究的尿生物标志物。
本系统评价按照 PRISMA 指南进行。筛选在 PUBMED 上进行,没有任何出版日期限制。仅纳入原始文章。获得与以下主题相关的参数:研究设计、参与者特征、参与者数量、年龄、对照组、生物标志物类型、尿液测量技术、亚组分析、尿动力学发现和结果。荷兰考科兰中心检查表(DCC)和 EBRO 平台的证据水平用于质量评估。使用 Comprehensive Meta-Analysis Version 4 程序进行荟萃分析。
共筛选出 494 项研究,纳入 16 项研究。其中 11 项(68.75%)在非神经源性 LUTD 患儿中进行,5 项(31.25%)在神经源性 LUTD 患儿中进行。有 12 项研究评估了神经生长因子(NGF),5 项研究评估了脑源性神经营养因子(BDNF),2 项研究评估了基质金属蛋白酶-2 抑制剂(TIMP-2),2 项研究评估了转化生长因子β-1(TGF Beta-1),1 项研究评估了中性粒细胞明胶酶相关脂质运载蛋白(NGAL),1 项研究评估了水通道蛋白-2。根据 DCC,10 项(62.5%)文章在 4 项(37.5%)项目中进行评估,4 项文章在 5 项项目中进行评估。平均得分为 3.91+/-0.56。证据水平为 B 级的有 13 项(81.25%),C 级的有 3 项(18.75%)。荟萃分析显示,非神经源性 LUTS 患儿的尿 NGF 水平明显高于健康对照组(Hedges's g=1.867,标准误差=0.344,方差=0.119,p=0.0001)。
尿生物标志物具有非侵入性特征,具有广阔的应用前景。然而,需要进行更大样本量的前瞻性研究,以更好地了解尿生物标志物在反映儿童 LUTD 尿动力学和临床发现方面的潜力。